



**XIIDRA
(lifitegrast ophthalmic solution)**

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Xiidra (lifitegrast) ophthalmic solution is used to treat dry eye disease. Xiidra is packaged in sterile, preservative-free single-use vials and is administered every 12 hours. Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. In patients whose tear production is presumed to be suppressed due to ocular inflammation due to dry eye disease, Xiidra increases tear production and is thought to act as a partial immunomodulator (1-2).

Regulatory Status

FDA-approved indication: Xiidra is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) (1).

The safety and effectiveness of Xiidra in pediatric patients less than 17 years of age have not been established (1).

Summary

Xiidra (lifitegrast) ophthalmic solution is used to treat chronic dry or decreased tear production. Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. In patients whose tear production is presumed to be suppressed due to ocular inflammation due to dry eye disease, Xiidra increases tear production and is thought to act as a partial immunomodulator. The safety and effectiveness of Xiidra in pediatric patients less than 17 years of age have not been established (1-2).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Xiidra while maintaining optimal therapeutic outcomes.

References

1. Xiidra [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; December 2023.
2. Dry Eyes Syndrome Preferred Practice Pattern. American Academy of Ophthalmology.



**BlueCross.
BlueShield.**

Federal Employee Program.

**XIIDRA
(lifitegrast ophthalmic solution)**

September 2018.